BioNexus Gene Lab (NASDAQ:BGLC) & Organon & Co. (NYSE:OGN) Head-To-Head Analysis

BioNexus Gene Lab (NASDAQ:BGLC) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Risk & Volatility

BioNexus Gene Lab has a beta of 4.06, suggesting that its share price is 306% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Profitability

This table compares BioNexus Gene Lab and Organon & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
Organon & Co.	3.99%	99.95%	6.22%

Insider and Institutional Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares BioNexus Gene Lab and Organon & Co.”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43 million	0.66	-$2.98 million	($1.48)	-1.38
Organon & Co.	$6.16 billion	0.58	$187.00 million	$0.93	14.52

Organon & Co. has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for BioNexus Gene Lab and Organon & Co., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1	0	0	0	1.00
Organon & Co.	2	5	0	0	1.71

Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 15.59%. Given Organon & Co.’s stronger consensus rating and higher possible upside, analysts clearly believe Organon & Co. is more favorable than BioNexus Gene Lab.

Summary

Organon & Co. beats BioNexus Gene Lab on 11 of the 13 factors compared between the two stocks.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.